Related by context. All words. (Click for frequent words.) 70 radical prostatectomy 68 clinically localized prostate 67 metastatic prostate cancer 66 breast conserving 65 hormonal therapy 65 prostate cancer 65 androgen deprivation therapy 65 prostatectomy 65 metastatic renal cell carcinoma 65 adjuvant therapy 65 prostate cancer CRPC 63 adjuvant chemotherapy 63 endometrial cancer 63 HER2 positive breast cancer 63 chemoradiation 62 cystectomy 62 adjuvant radiotherapy 62 recurrent prostate cancer 62 epithelial ovarian cancer 61 renal tumors 61 adjuvant radiation 61 metastatic disease 61 CaP 61 Radical prostatectomy 60 androgen deprivation 60 stage IIIB 60 preoperative chemotherapy 60 colorectal liver metastases 60 colorectal cancer 60 seminoma 60 prostate cancer HRPC 60 renal cell carcinoma 60 EBRT 60 HNSCC 60 neoadjuvant chemotherapy 60 neoadjuvant 60 metastatic RCC 60 oophorectomy 60 prophylactic mastectomy 60 prostate cancer CaP 60 endarterectomy 60 pancreatic adenocarcinoma 60 fallopian tube carcinoma 60 metastatic breast cancer 60 NSCLC 60 biochemical recurrence 59 neoadjuvant therapy 59 medically inoperable 59 neoplasia 59 radical nephrectomy 59 axillary dissection 59 cytoreductive surgery 59 hepatocellular carcinoma 59 IV NSCLC 59 external beam radiotherapy 59 rectal cancer 59 differentiated thyroid 59 prostate cancers 59 unresectable 58 symptomatic fibroids 58 radical cystectomy 58 malignant pleural mesothelioma 58 Barrett esophagus 58 non squamous NSCLC 58 watchful waiting 58 grade gliomas 58 carotid endarterectomy 58 neoplasia PIN 58 lymphadenectomy 58 partial nephrectomy 58 PCa 58 radical prostatectomy RP 58 breast cancer recurrence 58 PSA screening 57 ovarian cancer 57 gastric cancer 57 recurrent ovarian cancer 57 radiation therapy 57 metastatic castration resistant 57 undergoing radical prostatectomy 57 recurrent NSCLC 57 curative resection 57 locoregional 57 lymph node dissection 57 rectal cancers 57 tumor recurrence 57 transurethral resection 57 colorectal cancer CRC 57 castration resistant prostate cancer 57 resectable 57 prostate cancer PCa 57 TURP 57 CMV disease 57 brain metastases 57 beam radiotherapy 57 advanced NSCLC 57 radiation therapy SBRT 57 lymph node removal 57 endometrial carcinoma 56 lobular carcinoma 56 Adjuvant chemotherapy 56 GnRH agonists 56 chemoradiotherapy 56 hormone receptor positive 56 distant metastases 56 prostate specific 56 carotid artery stenting 56 invasive breast cancer 56 uterine fibroids 56 pelvic lymphadenectomy 56 hormone refractory prostate cancer 56 adenomatous polyps 56 tamoxifen therapy 56 severe aortic stenosis 56 endometrial cancers 56 prostate biopsy 56 hormonal therapies 56 orchiectomy 56 androgen deficiency 56 carotid stenosis 56 lumpectomy 56 perioperative morbidity 56 sentinel lymph node biopsy 56 prostate cancer mCRPC 56 metastatic cancer 56 pre menopausal 56 operable breast cancer 56 serum PSA 56 advanced adenomas 56 advanced neoplasia 56 hormone therapy 56 lymph node involvement 56 adenoma 56 carcinoma 56 antiplatelet therapy 56 prostate specific antigen 56 venous thromboembolism 56 nephron sparing surgery 56 cytoreduction 56 metastatic colorectal cancer 56 liver resection 56 postoperative chemotherapy 55 Metastatic Prostate Cancer 55 advanced adenoma 55 superficial bladder cancer 55 pancreatic NET 55 breast carcinoma 55 ALND 55 cervical lesions 55 taxane therapy 55 esophagectomy 55 epithelial ovarian 55 resistant ovarian cancer 55 laryngeal cancer 55 ductal breast cancer 55 postmenopausal women 55 histologically confirmed 55 bilateral oophorectomy 55 endometrial hyperplasia 55 underwent prostatectomy 55 castrate resistant prostate cancer 55 gastrointestinal cancers 55 HER2 positive metastatic breast 55 cirrhotic patients 55 Androgen deprivation therapy 55 symptomatic BPH 55 cervical carcinoma 55 breast tumors 55 pCR 55 axillary node dissection 55 colorectal cancers 55 metastatic GIST 55 colorectal polyps 55 sentinel node biopsy 55 gastric cancers 55 BRCA mutations 55 leukemia AML 55 ovarian carcinoma 55 liver metastases 55 premenopausal 55 cytoreductive nephrectomy 55 preventive mastectomy 55 urothelial cancer 55 screening mammography 55 relapsed ovarian cancer 54 beta blocker therapy 54 recurrent glioblastoma multiforme 54 cytotoxic chemotherapy 54 antigen PSA 54 urinary symptoms 54 intravesical therapy 54 prostate TURP 54 osteoporotic fractures 54 esophageal adenocarcinoma 54 NSTE ACS 54 prostate carcinoma 54 distant metastasis 54 colon cancer 54 underwent radical prostatectomy 54 hepatocellular carcinoma HCC 54 bladder cancers 54 Benign Prostatic Hyperplasia BPH 54 androgen suppression therapy 54 nonmelanoma skin cancer 54 metastatic melanoma 54 undergone radical prostatectomy 54 metastatic colon cancer 54 cutaneous melanoma 54 mRCC 54 neoadjuvant treatment 54 contralateral breast cancer 54 ICD implantation 54 Rectal cancer 54 colorectal neoplasia 54 estrogen therapy 54 lymph node metastases 54 grade glioma 54 screening colonoscopy 54 bladder cancer 54 stable angina 54 robotic prostatectomy 54 bone metastases 54 chemotherapy regimens 54 metastatic malignant melanoma 54 basal cell carcinoma BCC 54 hyperplasia BPH 54 situ CIS 54 premenopausal women 54 endosonography 54 colorectal adenoma 54 bone metastasis 54 optical colonoscopy 54 Doxil ® 54 perioperative mortality 54 endovascular repair 54 revascularization procedures 54 pelvic lymph node dissection 54 rectal carcinoma 54 Neoadjuvant 54 refractory ovarian cancer 54 carotid surgery 53 precancerous cervical lesions 53 preoperative radiotherapy 53 IV melanoma 53 microsphere therapy 53 nodal metastases 53 FOLFOX4 53 metastases 53 PSADT 53 eribulin 53 Accelerated Partial Breast Irradiation 53 intraperitoneal chemotherapy 53 hepatectomy 53 RALP 53 pneumonectomy 53 mCRC patients 53 Sentinel node biopsy 53 CT colonography CTC 53 grade cervical intraepithelial 53 gastrointestinal stromal tumor GIST 53 mycophenolate mofetil 53 locoregional recurrence 53 vandetanib 53 paclitaxel eluting stents 53 DCIS 53 vinorelbine 53 bladder carcinoma 53 HER2 negative 53 prostate cancer AIPC 53 metachronous 53 invasive coronary angiography 53 nonmetastatic prostate cancer 53 LUTS 53 atypical hyperplasia 53 lobular cancer 53 adenomas 53 TAVI 53 micrometastases 53 androgen suppression 53 advanced epithelial ovarian 53 peritoneal cancer 53 androgen independent 53 prostate adenocarcinoma 53 renal cell carcinomas 53 anthracyclines 53 basal cell cancers 53 female endoscopist 53 intestinal metaplasia 53 EUS FNA 53 bisphosphonate therapy 53 metastatic castrate resistant 53 postmenopausal breast cancer 53 CIN3 53 estrogen receptor positive 53 endocrine therapy 53 menopausal symptoms 53 invasive cervical cancer 53 pancreatic cancer 53 revascularization 53 radiotherapy SBRT 53 metastatic HRPC 53 anastrozole 53 endocrine therapies 53 stereotactic radiotherapy 53 underwent brachytherapy 53 postoperative atrial fibrillation 53 Hepatocellular Carcinoma HCC 53 malignancies 53 urothelial carcinoma 53 thyroid nodules 53 SHPT 53 cisplatin chemotherapy 52 perimenopausal women 52 brachytherapy 52 carotid artery disease 52 renal transplantation 52 palliation 52 hepatic metastases 52 testosterone supplementation 52 colorectal neoplasms 52 cell lung cancer 52 parathyroidectomy 52 transcatheter aortic valve implantation 52 HoLEP 52 radiofrequency ablation RFA 52 premenopausal breast cancer 52 invasive candidiasis 52 stenting 52 axillary lymph nodes 52 vertebral fracture 52 invasive lobular carcinoma 52 medullary thyroid cancer 52 coronary angiography 52 contralateral breast 52 allogeneic stem cell 52 breast cancer 52 gemcitabine 52 surgical excision 52 lung tumors 52 symptomatic carotid stenosis 52 BRCA2 mutations 52 peritoneal carcinomatosis 52 dacarbazine chemotherapy 52 lobectomy 52 abdominal hysterectomy 52 R0 resection 52 gynecologic cancer 52 KRAS mutations occur 52 balloon brachytherapy 52 hepatocellular cancer 52 hepatic resection 52 CIN2 + 52 unresectable tumors 52 placebo dexamethasone 52 metastatic 52 SLNB 52 DVT PE 52 tumor resection 52 prostrate cancer 52 nonmetastatic 52 tumors 52 heavily pretreated 52 vaginal atrophy 52 oncologic outcomes 52 polyp recurrence 52 uterine fibroid embolization 52 nerve sparing 52 thromboembolic events 52 hormone deprivation 52 platinum refractory 52 situ DCIS 52 soft tissue sarcomas 52 TACE 52 antihypertensive therapy 52 cytotoxic therapy 52 systolic hypertension 52 Surgical resection 52 asymptomatic carotid stenosis 52 breast irradiation 52 BRCA mutation carriers 52 conventional angiography 52 postoperative AF 52 breast cancers 52 nonoperative 52 metastatic pancreatic cancer 52 Cystectomy 52 warfarin therapy 52 BRCA2 mutation carriers 52 symptomatic uterine fibroids 52 acute coronary syndromes 52 renal dysfunction 52 subclinical hypothyroidism 52 debulking surgery 52 stage IIIB IV 52 HER2 positive 52 prostate pancreatic 52 malignancy 52 stereotactic body 52 CABG 52 dacarbazine 52 menopausal hormone therapy 52 everolimus eluting stents 52 colorectal carcinoma 52 squamous cell cancers 52 anticoagulation therapy 52 Prostate Lung Colorectal 51 invasive carcinoma 51 HBeAg negative 51 carotid artery stenting CAS 51 benign prostatic hyperplasia 51 adrenalectomy 51 recurrent colorectal cancer 51 Carcinoma 51 adjuvant therapies 51 ductal carcinoma 51 estrogen progestin therapy 51 advanced metastatic prostate 51 mitral regurgitation 51 squamous cell 51 dual antiplatelet therapy 51 pancreatic cancers 51 adenocarcinoma 51 breast lesions 51 docetaxel chemotherapy 51 metastatic gastric 51 Cristofanilli 51 pre cancerous lesions 51 stage IIIb IV 51 tamoxifen 51 PSA velocity 51 specific antigen PSA 51 grade dysplasia 51 diagnosed multiple myeloma 51 cardiotoxicity 51 axillary lymph node dissection 51 acute ischemic stroke 51 pancreatic neuroendocrine tumors 51 fibroadenomas 51 adenoma recurrence 51 postoperative pulmonary 51 transplant ASCT 51 lupus nephritis 51 trastuzumab 51 chemoradiation therapy 51 nephrectomy 51 curative therapy 51 catheter angiography 51 lipid lowering therapy 51 relapsed SCLC 51 hereditary breast cancer 51 primary peritoneal 51 ASCUS 51 recurrent ovarian 51 focal cryoablation 51 PSA nadir 51 statin therapy 51 LHRH agonist 51 recurrent VTE 51 prostate 51 ductal cancer 51 enlarged prostates 51 prognostic variables 51 antibiotic prophylaxis 51 bevacizumab Avastin ® 51 chlorambucil 51 osteoporotic 51 osteoporotic fracture 51 knee osteoarthritis 51 chemotherapy regimen 51 virologic failure 51 tumor shrinkage 51 free survival PFS 51 nonmelanoma skin cancers 51 prophylactic mastectomies 51 follicular lymphoma 51 liver transplantation 51 radical retropubic prostatectomy 51 Digital Mammographic Imaging 51 squamous cell cancer 51 refractory angina 51 cardiovascular morbidity 51 AVODART 51 fecal incontinence 51 prostate biopsies 51 Androgen Deprivation Therapy 51 prostates removed 51 stage IIIb 51 HRPC 51 WBRT 51 cabazitaxel 51 coronary disease 51 recurrent preterm birth 51 GISTs 51 precancerous lesions 51 postoperative mortality 51 oropharyngeal cancer 51 poorer prognosis 51 Invasive Breast Cancer 51 undergo radical prostatectomy 51 surgical resection 51 preoperative 51 secondary hypogonadism 51 testicular cancers 51 core needle biopsy 51 conventional coronary angiography 51 undergone hysterectomy 51 esophageal cancer 51 ductal carcinomas 51 CT colonography 51 diffuse gastric 51 estrogen receptor negative 51 alkylating agent 51 recurrent GBM 51 lung metastases 51 adenomatous 51 tuberous sclerosis TS 51 undergo prostate biopsy 51 Metastatic 51 colorectal adenomas 51 Benign prostatic hyperplasia BPH 51 thyroidectomy 51 gynecologic cancers 51 disease progression 51 contrast induced nephropathy 51 antidepressant therapy 51 metastatic colorectal 51 colectomy 51 vasomotor symptoms 51 unresectable stage 51 resection 51 chronic lymphocytic leukemia CLL 51 alkylating agents 51 nonsmall cell lung cancer 51 chemotherapy 51 liver transplant recipients 51 total thyroidectomy 51 glioma tumors 51 allogeneic hematopoietic stem cell 51 chemotherapy cisplatin 50 HGPIN 50 BRCA1 mutation carriers 50 radiofrequency ablation 50 Radiation therapy 50 paclitaxel carboplatin 50 carboplatin paclitaxel 50 serum prostate 50 IV metastatic melanoma 50 elevated CRP 50 basal cell carcinomas 50 curable cancers 50 Screening Trial 50 malignant lesions 50 metastatic lung cancer 50 meningioma 50 liver cancer 50 relapsed MM 50 transarterial chemoembolization 50 aldosterone antagonists 50 extrapleural pneumonectomy 50 colorectal cancer liver metastases 50 mucinous 50 lymphoma CTCL 50 cranial irradiation 50 cervical intraepithelial neoplasia 50 Faslodex 50 DMARD therapy 50 melanoma 50 Prostate Specific Antigen PSA 50 APTIVUS r 50 chemoembolization 50 carotid endarterectomy CEA 50 leiomyomas 50 refractory multiple myeloma 50 prostate tumors 50 chronic hemodialysis 50 endometriosis ovarian cysts 50 uterine cancers 50 gastrectomy 50 ALCL 50 distal colon cancer 50 severe neutropenia 50 gynecologic oncologists 50 situ LCIS 50 cervical dysplasia 50 intravenous bisphosphonates 50 preventive mastectomies 50 relapsing MS 50 paroxysmal AF 50 Hormone therapy 50 conventional colonoscopy 50 relapsing remitting multiple sclerosis 50 chemotherapy docetaxel 50 urolithiasis 50 hormone therapy estrogen 50 carotid stenting 50 cT3 prostate cancer 50 benign prostatic hypertrophy 50 squamous cell carcinoma SCC 50 sleeve lobectomy 50 erlotinib Tarceva ® 50 IV malignant melanoma 50 coronary stenting 50 ALA PDT 50 heavily pretreated patients 50 decitabine 50 colon tumors 50 temsirolimus 50 post menopausal 50 chlamydial infection 50 HER2 positive cancers 50 cholecystectomy 50 coronary revascularization 50 metastatic kidney 50 Hodgkin lymphoma HL 50 androgen ablation 50 gallstone disease 50 squamous cell carcinomas 50 epithelial tumors 50 carcinoid tumors 50 chronic ITP patients 50 minimally symptomatic 50 abnormal mammograms 50 urinary tract symptoms LUTS 50 FDG PET 50 inconclusive Pap 50 SIR Spheres microspheres 50 percutaneous nephrolithotomy 50 chemotherapeutic regimens 50 uterine fibroid embolization UFE 50 Recurrence Score 50 elective PCI 50 OPCAB 50 pT2 50 varicocele 50 autoantibody positive 50 postoperative morbidity 50 excisional biopsy 50 thoracoscopic lobectomy 50 breast endometrial 50 mitral valve repair 50 carcinoid tumor 50 radioiodine therapy 50 recurrent metastatic 50 XELOX 50 HCV infected 50 malignant neoplasms 50 localized renal 50 Chronic Heart Failure 50 colorectal tumors 50 mild gestational diabetes 50 esophagogastric 50 invasive aspergillosis 50 trials RCTs 50 multimodality therapy 50 cetuximab 50 liver metastasis 50 resistant hormone refractory 50 Testicular cancer 50 oral anticoagulation 50 hormonal treatments 50 contralateral prophylactic mastectomy 50 axillary lymph node 50 ovarian tumors 50 atherothrombotic events 50 malignant melanoma 50 neuroendocrine tumors 50 LHRH receptor positive 50 venous thromboembolic events 50 esophageal cancers 50 ovarian cancers 50 BRCA gene mutations 50 follicular lymphoma FL 50 recurrent glioblastoma 50 chronic prostatitis 50 bevacizumab Avastin 50 fallopian tube cancers 50 fluorouracil 50 refractory prostate cancer 50 urinary tract symptoms 50 resected 50 T2DM 50 prostate brachytherapy 50 MRgFUS 50 irinotecan chemotherapy 50 RF ablation 50 dose cytarabine 50 GnRH agonist 50 vertebral compression fractures 50 EGFR mutations 50 symptomatic benign prostatic 50 coronary artery disease 50 Imaging BSGI 49 metastatic bladder 49 cancer mCRC 49 gastrointestinal stromal tumor 49 F FDG PET 49 adjuvant tamoxifen 49 olaparib 49 Lumpectomy 49 metastatic pancreatic 49 radiochemotherapy 49 perioperatively 49 aromatase inhibitor therapy 49 atypical ductal hyperplasia 49 MR arthrography 49 postmenopausal hormone therapy 49 IIIB NSCLC 49 IMRT 49 aromatase inhibitors AIs 49 femoral neck fractures 49 varicoceles 49 Coronary Artery Bypass Graft 49 colorectum 49 nonsurgical treatment 49 spontaneous preterm delivery 49 node metastases 49 urothelial bladder cancer 49 peginterferon alfa 2a 49 DMARDs 49 severe menopausal symptoms 49 antithrombotic therapy 49 left ventricular dysfunction 49 dense breasts 49 nesiritide 49 BCG refractory 49 trabectedin 49 randomized trials 49 flutamide 49 mammography screening 49 T1a 49 trabeculectomy 49 myocardial infarction MI 49 gastrointestinal stromal tumors 49 non squamous 49 surgical aortic valve 49 percutaneous cryoablation 49 UroToday.com 49 ablative therapy 49 metastatic CRPC 49 ovarian lung 49 papillary 49 BENICAR HCT 49 neoplasias 49 repeat revascularization 49 nonhormonal 49 DMARD 49 vaginal hysterectomy 49 pulmonary metastases 49 HBV infection 49 intensity modulated radiotherapy IMRT 49 venous thromboembolism VTE 49 Hysterectomy 49 underwent resection 49 hypercalcemia 49 therapy IMRT 49 hemodialysis patients 49 cerebral infarction 49 metastatic renal cell 49 sunitinib 49 myomectomy 49 osteopenic 49 Flu Cy 49 Alessandro Riva 49 pegylated liposomal doxorubicin 49 subclinical hyperthyroidism 49 endometrial ablation 49 pelvic radiotherapy 49 luteinizing hormone releasing 49 solid organ transplantation 49 folate supplementation 49 gonococcal infections 49 hepatocellular carcinomas 49 laparoscopic procedures 49 SBRT 49 CYPHER Stent 49 cancerous prostate 49 transitional cell carcinoma 49 AA Amyloidosis 49 neoplasms 49 salpingo oophorectomy 49 Acute Myeloid Leukaemia AML 49 Malignant Melanoma 49 gynecological cancer 49 aspirin therapy 49 relapsed refractory multiple myeloma 49 surgical revascularization 49 abiraterone 49 enlarged prostate 49 undetectable PSA 49 Carotid artery stenting 49 standard chemotherapy regimens 49 glioma 49 total knee arthroplasty 49 multiple myeloma 49 subtrochanteric 49 transcervical 49 robotic radical prostatectomy 49 postmenopausal osteoporotic women 49 colon rectal cancer 49 pT3 49 mCRC 49 imatinib therapy 49 metastatic squamous cell carcinoma 49 anthracycline therapy 49 NAFLD 49 pelvic malignancies 49 B Cell Lymphoma 49 NMIBC 49 hysterectomy 49 duplex ultrasonography 49 fludarabine 49 5-fluorouracil/leucovorin 49 malignant growths 49 malignant lymphoma 49 cholangiocarcinoma 49 liposomal doxorubicin 49 chemo radiotherapy 49 skin sparing mastectomy 49 gemcitabine Gemzar 49 BRCA testing 49 IORT 49 docetaxel 49 NovoTTF 49 sorafenib Nexavar 49 5-FU/LV 49 Prostate cancer 49 reoperation 49 coronary artery bypass grafting 49 gefitinib 49 VTE 49 primary hypercholesterolemia 49 liposomal amphotericin B 49 thromboprophylaxis 49 donor nephrectomy 49 renal artery stenosis 49 endoscopic ultrasonography 49 unresectable liver cancer 49 surgical debulking 49 coronary calcification 49 advanced metastatic renal 49 proliferative diabetic retinopathy 49 concurrent chemoradiation 49 duodenal ulcer 49 TUMT 49 NATRECOR ® 49 ABVD 49 precursor lesions 49 papillary thyroid cancer 49 diabetes mellitus DM 49 pelvic organ prolapse 49 bowel resection 49 microalbuminuria 49 Radiofrequency ablation 49 spinal metastases 49 Osteoporotic Fractures 49 peginterferon 49 carcinomas 49 PREZISTA r 49 node dissection 49 lung resections 49 stage IIIA 49 doxorubicin HCl liposome injection 49 peripheral arterial disease 49 lung nodules 49 IV bisphosphonates 49 tumor histology 49 receiving highly emetogenic 49 PCNSL 49 undergo lumpectomy 49 cell carcinomas 49 lung resection 49 thromboembolic disease 49 EBUS FNA 49 intraductal 49 pegylated interferon alfa 2b 49 occlusive disease 49 kidney transplant recipients 49 acne vulgaris 49 indolent NHL 49 postoperative radiotherapy 49 DAPT 49 undergo mastectomy 49 Median survival 48 uterine artery embolization 48 capecitabine 48 solid tumors 48 bilateral mastectomy 48 sigmoidoscopy 48 cisplatin 48 adolescent idiopathic scoliosis 48 pleural mesothelioma 48 bilateral orchiectomy 48 serous ovarian cancer 48 uterine tumors 48 oesophageal cancer 48 operable pancreatic cancer 48 systemic lupus erythematosus SLE 48 endoscopic ultrasound 48 conformal radiotherapy 48 Transurethral Resection 48 cystoscopy 48 axitinib 48 patients undergoing CABG 48 cell carcinoma 48 PSA prostate 48 biliary strictures produced 48 BRCA mutation 48 lung transplantation 48 FOLFIRI 48 total abdominal hysterectomy 48 % CI #.#-#.# [003] 48 Uterine fibroids 48 postmenopausal 48 abnormal uterine bleeding 48 pancreatic resection 48 mastectomy 48 elevated LDL cholesterol 48 bowel cancers 48 hematological disorders 48 inguinal hernia repair 48 metastatic cancers 48 tamsulosin 48 Follicular Lymphoma 48 chronic HCV infection 48 gestational hypertension 48 chronic HCV 48 BRCA1 mutations 48 ovaries removed 48 moderate renal impairment 48 geographic atrophy 48 percutaneous coronary intervention 48 endoscopic resection 48 Zevalin consolidation 48 radiotherapy 48 ovulation induction 48 Prostate Cancer Prevention 48 Stereotactic Body Radiation Therapy 48 atypia 48 melanomas 48 occult metastases 48 urine cytology 48 secondary hyperparathyroidism 48 benign breast 48 follicular lymphomas 48 completely resected 48 venous thrombosis 48 prostatectomies 48 hypofractionated radiation 48 invasive bladder 48 upper gastrointestinal bleeding 48 BEACOPP 48 premalignant 48 FASLODEX 48 bortezomib 48 abdominal aortic aneurysms AAA 48 sacrocolpopexy 48 malignant polyps 48 colon rectal 48 metastatic neuroendocrine tumors 48 premature ejaculation PE 48 asymptomatic 48 grade cervical dysplasia 48 squamous cell carcinoma 48 fibroids 48 digital rectal exams 48 idarubicin 48 Hurthle cell 48 HER2 positive tumors 48 nonpregnant women 48 specific antigen 48 lung cancer 48 cell lymphoma CTCL 48 Renal Cell Carcinoma 48 Embolization 48 bicalutamide 48 sarcomatoid 48 vulvovaginal atrophy 48 primary hyperparathyroidism 48 intensity modulated 48 tibolone 48 gastrointestinal GI cancers 48 CT angiography 48 postoperative complication 48 unfractionated heparin 48 anthracycline taxane 48 metastatic malignant 48 pegylated liposomal doxorubicin PLD 48 PCIs 48 cutaneous squamous cell carcinoma 48 hypertensive patients 48 atherosclerotic disease 48 SilverHawk Plaque Excision System 48 metastatic ovarian cancer 48 invasive ductal carcinoma 48 Halaven 48 gemcitabine chemotherapy 48 dysplastic nevi 48 LNG IUS 48 Metastatic Breast Cancer